(AOF) – Noxxon Pharma announced on Friday evening that it had drawn additional tranches of financing from its financing agreement with Atlas Special Opportunities, LLC (ASO), for a total amount of 2.375 million euros and issued 2,419 convertible bonds ( including the 44 convertible bonds issued in connection with transaction costs) with a nominal value of 1,000 euros each. The remaining availability under the agreement with ASO extends the company’s financial visibility until December 2022.
AOF – LEARN MORE
Boost for French pharmacy
At the end of a recent CSIS, the French authorities announced an amount of credits (7 billion euros) never reached: 1.5 billion for hospital-university research, 2 billion for investment in health via bpi france , 1.5 billion in aid for the relocation of industrial projects, and 2 billion to strengthen investment in three sectors of the future (bioproduction, digital medicine, and pandemic preparedness). In addition, the annual growth in drug expenditure reimbursed by Medicare will be 2.4%, which should generate growth of at least 0.5% in the turnover of laboratories,
Above all, the normal drug marketing procedure will be accelerated (up to 500 days saved) if the medical benefit rendered is sufficient.